A large-scale Australian review identifies consistent inflammatory and immune biomarkers in the debilitating disease.
Irritable bowel syndrome is showing its biological hand, with converging evidence of immune activation, low-grade inflammation and altered gut biochemistry challenging its long-standing classification as a purely functional disorder and pointing toward measurable disease mechanisms with clinical relevance.
A comprehensive systematic review and meta-analysis led by the University of Newcastle has drawn together 124 studies spanning more than three decades and nearly 15,000 patients with IBS, alongside more than 7500 healthy controls and more than 4300 patients with organic gastrointestinal disease.
“The combined evidence from this study and previous literature supports IBS as a condition with measurable biological alterations in immune and inflammatory pathways,” the researchers wrote.
“With further characterisation, these findings continue to challenge the traditional view as a purely functional disorder and support the potential for biomarker-based diagnostic and treatment stratification tools.
“Clinically, such an approach would reduce reliance on symptom-based criteria and exclusionary testing, allowing for earlier and accurate diagnosis and tailored management.”
Results have been published in eBioMedicine.
University of Newcastle researcher Dr Grace Burns, of HMRI’s Immune Health Research Program, said the findings provided important evidence that IBS had measurable biological features.
“IBS has often been misunderstood as a purely functional disorder,” she said.
“Our findings show there are subtle but detectable biological changes, particularly involving the immune system.”
The work aligns with a broader shift in gastroenterology towards viewing IBS as a disorder of gut–brain interaction with underlying pathophysiological changes, rather than an absence of disease.
Using standardised mean differences to account for assay variability, the analysis identified consistent, statistically significant differences in both circulating and faecal biomarkers, despite substantial heterogeneity across studies.
The most robust signals were seen in peripheral cytokines. Tumour necrosis factor alpha, interleukin-6 and interferon gamma were all significantly elevated in IBS cohorts compared with healthy controls, with effect sizes in the moderate-to-large range.
These findings support a model of chronic, low-grade immune activation and are consistent with evidence of increased epithelial permeability, which may permit luminal antigens and microbial products to drive mucosal immune responses.
The persistence of these signals after sensitivity analyses suggests they are not driven by single outlier studies, although between-study variability remained high.
Faecal markers provided complementary insights. Calprotectin, a neutrophil-derived protein widely used in clinical practice to distinguish inflammatory bowel disease from functional disorders, was significantly elevated in IBS compared with healthy individuals, with a moderate effect size.
Related
However, levels remained markedly lower than those observed in organic disease, reinforcing its value in ruling out overt inflammation rather than confirming IBS, the researchers noted.
The data suggest a continuum of inflammatory activity, with IBS occupying an intermediate position between health and conditions such as Crohn’s disease and ulcerative colitis.
Short-chain fatty acid profiles also differed, with valerate levels reduced in IBS pointing to potential alterations in microbial metabolism. While the clinical utility of these metabolites remains uncertain, the findings added to a growing body of work implicating microbiome–host interactions in symptom generation and disease heterogeneity.
Subtype analyses, though limited by reporting inconsistencies, identified signals specific to diarrhoea-predominant IBS.
Patients with IBS-D showed significantly lower serum albumin and higher IL-6 levels than controls, suggesting a combination of inflammatory activity and possible nutritional or absorptive effects linked to chronic diarrhoea.
The relative lack of consistent markers in constipation-predominant and mixed subtypes highlights ongoing gaps in phenotypic stratification.
The study also examined markers that could differentiate IBS from organic gastrointestinal disease. Serum albumin was higher in IBS than in organic disease cohorts, while faecal calprotectin remained substantially lower, reinforcing the potential for combined biomarker panels to aid in differential diagnosis and reduce reliance on exclusion-based approaches.
For clinicians, the implications extended beyond pathophysiology, the researchers noted.
The identification of reproducible biomarker patterns raised the prospect of moving away from symptom-based Rome criteria alone toward adjunctive, objective measures.
While no single marker demonstrated sufficient specificity or sensitivity for standalone diagnosis, they said that multi-marker panels, potentially incorporating cytokines, faecal proteins and microbial metabolites, may offer a more reliable diagnostic framework.
The findings also carried relevance for patient communication and stigma reduction, the researchers said.
Demonstrating that IBS was associated with measurable immune and inflammatory changes may help validate patient experiences and support more nuanced clinical discussions, particularly in cases where symptoms were severe but conventional investigations were unremarkable.
Limitations remained substantial, however.
Heterogeneity across studies was consistently high, reflecting differences in diagnostic criteria, assay methods, geographic populations and subtype classification.
Many studies were underpowered, and IBS subtypes were frequently underreported or unevenly represented, particularly constipation-predominant disease. These factors continued to impede translation into routine clinical practice, the researchers said.
Nevertheless, the analysis provided one of the most comprehensive quantitative syntheses of IBS biomarkers to date and strengthens the case for a biologically informed reclassification of the condition, they said.
As research moved toward validation and standardisation of biomarker panels, the prospect of earlier, more accurate diagnosis and personalised treatment strategies appeared increasingly within reach.
“In summary, we have performed a comprehensive analysis of blood and faecal biomarkers in IBS and identified consistent cytokine and stool biomarkers associated with IBS,” the researchers concluded.
“These biomarkers may reflect increased epithelial permeability and thus low-grade bacteraemia in patients with IBS, and this may be suggestive of an underlying cause of IBS symptoms currently overlooked.
“In addition, care should be taken when using albumin and fCal to distinguish organic GI diseases from IBS-D.
“While caution should be taken in suggesting any one marker can be used to identify IBS, these data do add further evidence to the view that IBS pathology has an underlying immune basis.”
